Evolent Health R&D Spending Growth & History (EVH)

Evolent Health's r&d spending was $15.5M for fiscal 2021.

View full Evolent Health company overview

Evolent Health annual r&d spending history

Evolent Health annual r&d spending

Fiscal yearPeriod endedR&D spendingChangeGrowth
20212021-12-31$15.5M$400,000+2.65%
20202020-12-31$15.1M−$4.7M−23.74%
20192019-12-31$19.8M$1.6M+8.79%
20182018-12-31$18.2M$1.0M+5.81%
20172017-12-31$17.2M$6.1M+54.95%
20162016-12-31$11.1M$5.3M+91.38%
20152015-12-31$5.8M$5.8M
20142014-12-31$0−$2.0M
20132013-12-31$2.0M

Evolent Health r&d spending trends

Over the last five fiscal years, Evolent Health's r&d spending increased from $11.1M to $15.5M, a change of $4.4M. The latest reported quarter, Q3 2022, shows $3.8M.

About the metric

What research and development spending means

Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.

Calculation and source

SEC-reported R&D expense

TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Evolent Health source filings ↗

Community posts

It’s quiet here.

No posts about EVH yet. Start the conversation.

Write the first post